- Home
- HFFG vs CRVS Comparison
HFFG vs CRVS Comparison
Compare HFFG & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFFG
- CRVS
- Stock Information
- Founded
- HFFG N/A
- CRVS 2014
- Country
- HFFG United States
- CRVS United States
- Employees
- HFFG N/A
- CRVS N/A
- Industry
- HFFG Food Distributors
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- HFFG Consumer Discretionary
- CRVS Health Care
- Exchange
- HFFG Nasdaq
- CRVS Nasdaq
- Market Cap
- HFFG 168.8M
- CRVS 516.0M
- IPO Year
- HFFG N/A
- CRVS 2016
- Fundamental
- Price
- HFFG $2.95
- CRVS $5.10
- Analyst Decision
- HFFG
- CRVS Strong Buy
- Analyst Count
- HFFG 0
- CRVS 5
- Target Price
- HFFG N/A
- CRVS $12.38
- AVG Volume (30 Days)
- HFFG 46.2K
- CRVS 1.7M
- Earning Date
- HFFG 11-12-2024
- CRVS 11-12-2024
- Dividend Yield
- HFFG N/A
- CRVS N/A
- EPS Growth
- HFFG N/A
- CRVS N/A
- EPS
- HFFG N/A
- CRVS N/A
- Revenue
- HFFG $1,177,258,000.00
- CRVS N/A
- Revenue This Year
- HFFG $5.18
- CRVS N/A
- Revenue Next Year
- HFFG $2.73
- CRVS N/A
- P/E Ratio
- HFFG N/A
- CRVS N/A
- Revenue Growth
- HFFG 1.53
- CRVS N/A
- 52 Week Low
- HFFG $2.46
- CRVS $1.30
- 52 Week High
- HFFG $5.91
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- HFFG 29.57
- CRVS 36.16
- Support Level
- HFFG $2.93
- CRVS $4.93
- Resistance Level
- HFFG $3.30
- CRVS $6.47
- Average True Range (ATR)
- HFFG 0.11
- CRVS 0.40
- MACD
- HFFG -0.04
- CRVS 0.06
- Stochastic Oscillator
- HFFG 10.71
- CRVS 29.74
About HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The Company's business consists of one operating segment; HF Group, which operates solely in the United States. The Company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).